FOLR1 and ovarian carcinoma: REFRaME-O1 (NCT05870748) is a two-part phase II trial evaluating the efficacy and safety of luveltamab tazevibulin in patients with relapsed platinum-resistant epithelial ovarian cancer expressing folate receptor alpha.